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Background: Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program
aims to better characterize and manage this disease. We report the results of part I, a retrospective joint analysis of cases
diagnosed during a 20-year period.
Methods: Patients with follow-up and tumor samples, treated between 1990 and 2010, in 93 centers/9 countries. Samples were
centrally analyzed in three laboratories (the United Kingdom, the Netherlands and the United States).
Results: Of 1822 patients enrolled, 1483 were analyzed; 63.5% were diagnosed between 2001 and 2010, 57 (5.1%) had
metastatic disease (M1). Median age at diagnosis: 68.4 years. Of 1054 M0 cases, 56.2% were node-negative (N0) and 48.5% had
T1 tumors; 4% had breast conserving surgery (BCS), 18% sentinel lymph-node biopsy; half received adjuvant radiotherapy; 29.8%
(neo)adjuvant chemotherapy and 76.8% adjuvant endocrine therapy (ET), mostly tamoxifen (88.4%). Per central pathology, for
M0 tumors: 84.8% ductal invasive carcinomas, 51.5% grade 2; 99.3% estrogen receptor (ER)-positive; 81.9% progesterone
receptor (PR)-positive; 96.9% androgen receptor (AR)-positive [ER, PR or AR Allred score3]; 61.1% Ki67 expression low (<14%
positive cells); using immunohistochemistry (IHC) surrogates, 41.9% were Luminal-A-like, 48.6% Luminal-B-like/HER-2-negative,
8.7% HER-2-positive, 0.3% triple negative. Median follow-up: 8.2 years (0.0–23.8) for all, 7.2 years (0.0–23.2), for M0, 2.6 years (0.0–
12.7) for M1 patients. A significant improvement over time was observed in age-corrected BC mortality. BC-specific-mortality
was higher for men younger than 50 years. Better overall (OS) and recurrence-free survival (RFS) were observed for highly
VC The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Annals of Oncology 29: 405–417, 2018
doi:10.1093/annonc/mdx651
Published online 28 October 2017
ERþ (P¼ 0.001), highly PRþ (P¼ 0.002), highly ARþ disease (P¼ 0.019). There was no association between OS/RFS and HER-2
status, Ki67, IHC subtypes nor grade.
Conclusions: Male BC is usually ER, PR and AR-positive, Luminal B-like/HER2-negative. Of note, 56% patients had T1 tumors but
only 4% had BCS. ER was highly positive in>90% of cases but only 77% received adjuvant ET. ER, PR and AR were associated
with OS and RFS, whereas grade, Ki67 and IHC surrogates were not. Significant improvement in survival over time was observed.
Key words: male breast cancer, retrospective analysis, consortium, clinical and biological characteristics
Introduction
Male breast cancer (BC) is a rare disease that accounts for less
than 1% of all cancers in men [1] and about 1% of all BC [2].
Although its incidence increased by about 26% over the past
25 years, male BC focused basic and clinical research is limited,
and most available data come from observational retrospective
studies [2–4]. Several genetic disorders (e.g. Kleinefelter’s syn-
drome) can increase the risk of the disease by 50-fold [5]. A fam-
ily history of breast and ovarian cancer is reported in
approximately 15%–20% of men with BC, conferring a relative
risk of 2.5 [6]. Moreover, 10% of men with BC have a BRCA2
mutation, and fewer have a mutated BRCA1 [7]. The American
Society of Clinical Oncology (ASCO) therefore recommends that
all men with BC should be offered genetic counseling and testing,
regardless of family history [8]. Other genes reported to be
mutated in male BC patients are PTEN, p53 and CHEK2 [9].
Additional risk factors include obesity, testicular abnormalities
or pituitary adenomas that led to hormonal imbalance, gynaeco-
mastia, cirrhosis, exogenous estrogens in men (treated for pros-
tate cancer or transsexuals taking estrogens), race (black men
have increased incidence) and radiation exposure [8].
The management of male BC is mainly extrapolated from
knowledge about female BC [8]. Currently the most common
surgical management is a modified radical mastectomy, whereas
breast-conserving treatment (lumpectomy plus radiation ther-
apy) is carried out in no more than one in seven patients [10].
For chemotherapy and radiation therapy, similar indications and
regimens to female BC are used. Tamoxifen is the adjuvant endo-
crine treatment of choice and recommended for hormone-
receptor positive tumors, for at least 5 years [8, 11]. The use of
aromatase inhibitors in the adjuvant setting is discouraged. The
Advanced Breast Cancer (ABC) International Consensus
Guidelines state that in metastatic male BC patients who need
treatment with an aromatase inhibitor, a concomitant LHRH
agonist or orchiectomy is preferred [12, 13].
Many attempted male BC clinical trials to date have closed due
to lack of recruitment. There is an unmet need for dedicated
research for this disease, to improve understanding of the under-
lying biology and potential differences from female BC, and to
optimize its clinical management. Due to the rarity of this cancer,
dedicated research can only be successful if carried out in a world-
wide collaborative network. With this purpose, the European
Organization for Research and Treatment of Cancer (EORTC),
in collaboration with the Translational Breast Cancer Research
Consortium (TBCRC), the North American Breast Cancer
Group (NABCG) and the Breast International Group (BIG)
launched, in 2006, a global effort aiming to characterize the biol-
ogy of male BC and to develop clinical trials, called the
‘International Male BC Program’. This program consists of three
parts: a retrospective collection of male BC treated in participat-
ing centers, over 20 years, for whom centralized clinical informa-
tion and tumor samples were collected (part I); a prospective
registry of newly diagnosed cases during a period of approxi-
mately 30 months, with clinical data and tumor samples (part II);
and prospective clinical studies to optimize the management of
these patients (part III). This article describes the primary results
of part I.
Patients and methods
This retrospective cohort study enrolled male patients with histologically
proven BC, diagnosed between 1990 and 2010, in all participating institu-
tions. Patients with all disease stages (early, locally advanced and meta-
static) were included, irrespective of the treatment received. Availability
of a tissue sample (formalin fixed paraffin embedded; FFPE) of good
quality was mandatory for enrollment. Biological material was handled
and analyzed centrally according to published guidelines for adoption
across BC clinical trials, conducted by BIG and NABCG in 2009 [14].
Because there were three central laboratories assessing the main bio-
markers, one in the United States and two in Europe, common protocols
were developed to ensure a uniform analysis and reporting of the results.
This is a retrospective, descriptive study, with no a priori sample size.
The study was constructed to enroll a minimum of 500 patients and a
maximum of 1800. The objectives of the present analysis are to describe
patient and disease characteristics (including histological and pathologi-
cal markers), treatment(s) administered and clinical outcomes. Patient
outcomes [relapse-free survival (RFS), overall survival (OS)] are sum-
marized and stratified by key patient and disease characteristics. Analyses
were carried out separately for metastatic (M1) and nonmetastatic (M0)
tumors, when considered relevant. The association between the studied
biomarkers and RFS and OS was explored in M0 patients.
FFPE samples were initially analyzed at two central laboratories for estro-
gen receptor (ER), progesterone receptor (PR) androgen receptor (AR),
HER2 and Ki67 (N¼ 1483). Afterwards, the remaining European samples
were sent to a third central laboratory (Rotterdam) for the assessment of his-
tology, grade, fibrotic focus, mitotic activity index and inflammation density
(N¼ 1203). Of the latter, only grade and histology are included in this
manuscript, and all others are reported in a separate paper [15].
ER, PR and AR are reported by Allred scores; positivity was defined as
a score 3; with high positivity as a score of seven or eight [16]. HER2
status is characterized per ASCO-CAP guidelines and BC subtype surro-
gates are characterized according to an adaptation of the 2013 St Gallen
consensus guidelines [17, 18]. Definition of immunohistochemistry
(IHC) surrogates for BC subtypes as adapted from the St Gallen consen-
sus guidelines and their operationalization within the study are detailed
in Table 1. For BC subtype surrogate definition, level of Ki-67 expression
was reported as the proportion of positive cells as follows: low
expression<20% and high expression: 20% [18]. The low expression
level was further dichotomized (< 14%, and14% to<20%) for
descriptive purposes only to have a more detailed overview accounting
for the inter-laboratory measurement variability in Ki-67 measurement.
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Grading was carried out according to Bloom and Richardson
Nottingham modification.
Laboratory methods
Tissue blocks were received at central laboratory, logged, reviewed for
sufficient tissue and subjected to pathology quality assurance and tissue
marking. Then six cores (0.6 mm2) were extracted and placed on six rep-
licate tissue microarrays (TMAs). Standard IHC techniques were used to
stain triplicate TMAs for ER (SP1; Roche/Ventana, United Kingdom),
PR (Clone 16; Leica/Novocastra, United Kingdom), AR (Clone
ER179(2); Abcam, United Kingdom), Ki67 (MIB1; DAKO, United
Kingdom) and HER-2 (Clone 45B; Roche/Ventana). Assays were carried
out using the Ventana Benchmark XT (Ventana Medical Systems) auto-
mated stainer using a single batch of antibody and reagents. Each run
included a quality-control TMA possessing samples with varying expres-
sion of each marker and runs were accepted only if histoscore interrun
variation was<15%. Imaging of the stained slides was carried out using
the Ariol SL-50 image analysis system (Leica Biosystems, Newcastle,
United Kingdom) using previously validated algorithms [19]. Each TMA
was scanned, mapped to positional map and individually assessed for
tumor content (tumor areas were marked and checked and a second
pathology quality assurance assessment was carried out). The actual
number and percentage of cells in each category were recorded, with a
minimum of 100 tumor cells per marker and per patient required for eli-
gibility. Membrane staining and scoring for HER-2 utilized similarly vali-
dated algorithms using Definiens Tissue Studio v2.1 (Definiens, Munich,
Germany). HER-2 protein was considered positive if IHC staining
3þ and negative for IHC 0 and 1þ [20]. In cases where IHC was equivo-
cal (2þ), fluorescence in situ hybridization (FISH) using the Vysis
Pathvision HER-2 probe set (Abbott Laboratories) was used to determine
HER-2 positivity according to the 2013 ASCO-CAP guidelines [17].
FISH was carried out according to the manufacturer’s instructions. The
TMAs were imaged and analyzed using the BioView Imaging System
(BioView, Billerica, MA) with FDA and CE-marked imaging/scoring sol-
utions for HER2/CEP17.
Statistical analysis
Statistical analysis of clinical data, long-term outcomes and local and cen-
tral pathology data were carried out centrally at EORTC. The analysis
population consists of patients eligible for the study and for whom a cen-
tral pathology assessment for at least ER, PR, AR, HER-2 or Ki67 was
available. Descriptive statistical analysis was carried out for patient, dis-
ease characteristics and treatment(s) administered. Time trends in treat-
ment administration were investigated using the score test in a logistic
model (generalized logistic for breast surgery, nodal management che-
motherapy regimen and endocrine treatments) with the date of diagnosis
expressed in decades as a covariate. The reported percentages in the
Results section are based on the number of nonmissing values as the
denominator. In the tables, the amount of missing data is reported, as
well as the percentages including or excluding the missing data.
RFS is defined as the time until the first loco-regional recurrence, dis-
tant progression or death due to any cause; and only defined within the
subset of M0 patients, for whom local recurrence, distant progression
and survival status/dates are not missing.
BC-specific mortality (BCSM) is defined as the time until death, if
death is preceded by a distant relapse, and only defined in the subset of
patients for whom distant relapse information and survival status/dates
are not missing; all other deaths are censored at the death date.
Time-to-Distant Relapse is defined only in the subset of M0 patients
for whom distant relapse information and survival status/dates are not
missing. Deaths in the absence of distant recurrence are considered as
competing risk.
OS is defined as the time until date of death (due to any cause). OS was
only defined within the subset of patients for whom survival status/dates
were not missing.
The endpoints were calculated from the time of first diagnosis of BC.
Patients without an event for the above endpoints were censored at the
last date known alive. Kaplan–Meier curves were drawn for three main
patient categories: lymph node negative early BC (M0N0), lymph node
positive early BC (M0Nþ) and metastatic BC (M1).
Table 1. BC subtype surrogate definition based on an adaptation of the 2013 St Gallen Consensus guidelines
Subtype 2013 St Gallen Consensus definition [15] Operationalization within the study
Luminal A-like ER positive AND ER Allred score 3 AND
PR positivea AND PR Allred score5 AND
HER2 negative AND HER2 negative AND
Ki-67 ‘low’ Ki-67 <20%
Luminal B-like (HER2 negative) ER positive AND ER Allred score3 AND
HER2 negative AND HER2 negative AND
(Ki-67 ‘high’b OR (Ki-67 20% OR
PR ‘negative or low’a) PR Allred score <5)
Luminal B-like (HER2 positive) ER positive AND ER Allred score3 AND
HER2 over-expressed or amplified HER2 positive
Any Ki-67
Any PR
HER2 positive (nonluminal) ER absent AND ER Allred score<3 AND
PR absent AND PR Allred score <3 AND
HER2 over-expressed or amplified HER2 positive
Basal ER absent AND ER Allred score <3 AND
PR absent AND PR Allred score<3 AND
HER2 negative HER2 negative
aA low PR value may be used to distinguish between Luminal-A like and Luminal-B like (HER2-negative).
bA majority of the panel voted that a threshold of20% was indicative of ‘high’ Ki-67 status.
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For 473 patients from the Netherlands, a survival update was received
before database lock, which was only informative regarding survival sta-
tus without disease assessment information nor cause of death.
Therefore, these data were only used for OS analyses.
OS and RFS were analyzed per Kaplan–Meier method, reported hazard
ratios (HR) were based on univariate Cox Models and P-values on the
score test (equivalent to the unadjusted logrank test in case of two
groups).
For age-corrected BCSM by period of diagnosis (1990–1995, 1996–
2000, 2001–2005, 2006–2010), patients were classified into four age
groups (41–50, 51–60, 61–70, 71–80); each group received a constant
weight across each time period, proportional to the total number of
patients in that age group. Patients outside these groups were excluded.
In the Kaplan–Meier analysis, mortality curves rather than survival
curves are shown for this endpoint. The reported risk sets are those from
the unweighted analysis by time period.
Role of the funding source
The funding source had no role in study design or conduct, data collec-
tion, data management, data analysis, data interpretation or writing of
the report.
Results
Patient and disease characteristics
Of 1822 patients enrolled, 22 (1.2%) were ineligible based on
clinical characteristics and 317 (17.6%) were ineligible since no
specimen was available for central pathology assessment, leaving
1483 patients for the present analysis (Table 2). Median follow-
up was 8.2 years (range: 0.0–23.8) for all patients and 7.2 years
(range: 0.0–23.2), for M0 patients.
Median age at diagnosis was 68.4 years, with only 24 (1.6%)
patients diagnosed younger than 40 years.
Among patients with known M status at diagnosis, the major-
ity (1054 patients, 94.9%) were diagnosed with early BC and
approximately half of these (592 patients, 56.2%) with N0 dis-
ease. The number of patients diagnosed with de novo metastatic
disease was 57 (3.8%). For 372 patients (25.1%) information on
M status at diagnosis is lacking. Table 3 describes patients and
disease characteristics for every 5-year period from 1990 to 2010
and overall.
Treatment
Patterns of treatment are detailed in Table 4. The vast majority of
M0 patients 794 (95.9%) underwent (modified) radical mastec-
tomy, with only 4% (33 patients) treated with breast conserving
surgery (BCS). Most (76.4%, 628) patients underwent axillary
nodal dissection with or without previous sentinel lymph-node
biopsy (SLNB), whereas 17.9% had SLNB only. The proportion
of patients with surgical axillary management increased signifi-
cantly throughout the years (trend over time P< 0.001).
Post-mastectomy adjuvant radiation therapy (RT) was deliv-
ered to 130 N0 patients (31.6%) and to 237 Nþ patients (68.1%).
Among patients treated with BCS, all Nþ and 10 (45.5%) N0
patients received adjuvant RT (supplementary Table S1, available
at Annals of Oncology online). Adjuvant chemotherapy was
administered to 245 (29.8%) patients, 105 (42.3%) patients with
an anthracycline-based regimen, 79 (32.3%) patients with an
anthracycline and taxane–based regimen and 36 (14.6%) patients
with CMF. Adjuvant endocrine therapy (ET) was prescribed to
627 (76.8%) patients, primarily with tamoxifen. About 3% (32
patients) received aromatase inhibitors and 2.5% (26 patients) a
sequence of tamoxifen followed by an aromatase inhibitor, for a
total duration of 5 years. A significant trend over time for a higher
percentage of adjuvant ET use is observed (P<0.001). Among 32
HER-2-positive patients, diagnosed from 2006 onwards, 75% (15
patients) received adjuvant trastuzumab.
Central pathology review
Central pathology data for M0 patients (1054 patients) are shown
in Table 5. The majority (84.8%) were invasive ductal carcino-
mas, mainly (51.5%) histologic or Nottingham grade 2. Almost
all were ER positive (99.3%), with 93.4% highly positive. PR posi-
tivity was present in 81.9% of cases, highly positive in 37.8%. AR
positivity was found in 96.9%, highly positive in 87.6%. HER-2
positivity was seen in 91 patients (8.7%). Ki-67 expression was
centrally assessed in 1033 samples: 778 (75.1%) had<20% posi-
tive cells including [633 (61.1%) with<14% positive cells and
145 (14.0%) with14% and<20% positive cells] and 255
(24.9%) had20% positive cells corresponding to high Ki-67
expression. Most patients had a luminal-like BC subtype (based
on IHC surrogates), with 48.6% Lumina-B-like/HER-2-negative
and 41.9% Luminal-A-like. HER-2-positive subtype was found
in 9.1% of cases, mostly Luminal-B-like-HER-2-positive, and
0.3% were triple negative.
Central pathology review data for the 57 patients with M1 dis-
ease at diagnosis are summarized in supplementary Table S2,
available at Annals of Oncology online.
Overall outcomes
Median OS was 10.4 years [95% confidence intervals (CI), 8.8–
11.8] in early BC N0M0, 8.4 years (95% CI, 7.1–9.4) in early BC
NþM0 and 2.6 years (95% CI, 2.0–3.7) in M1, respectively
(Figure 1). Supplementary Table S3, available at Annals of
Oncology online, describes disease status data for M0 and M1
patients. Of M0 patients, 36.3% died due to disease progression
(40.9% missing that information). Among M0 patients, median
RFS by nodal status was 8.6 years (95% CI, 7.4–11.2) for N0 and
6.4 years (95% CI, 5.8–7.5) for N-N3 disease (Figure 1).
Supplementary Figure S1, available at Annals of Oncology online,
shows RFS according to tumor size, supplementary Figure S2,
available at Annals of Oncology online, shows BCSM by disease
status and supplementary Figure S3, available at Annals of
Oncology online, shows time-to-distant relapse for M0 patients
by nodal status.
There were 112 second primary cancers diagnosed, with a
cumulative incidence of 8.8% at 5 years and 15.3% at 10 years.
The most common cancers were prostate (26.7%), colorectal
(11.6%), lung (10.7%) and non-melanoma skin cancer (8.9%)
(supplementary Table S4, available at Annals of Oncology online).
Outcomes in relation to period of diagnosis and
age
Mortality and BCSM were calculated for every 5-year period
from 1990 till 2010. Overall mortality decreased significantly over
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the study period, from 44.8% (95% CI, 38.5–51.7) in 1990–1995
to 26.9% (95% CI, 22.6–31.9) in 2006–2010 (Figure 2A). There is
a less pronounced improvement in BCSM over time, especially
after the nineties, as measured by age-corrected BCSM (Figure 3).
The 5-year age-corrected BCSM rates were 15.1% (95% CI, 14.4–
15.8) for cases diagnosed between 1990 and 1995, 8.3% (95% CI,
7.8–8.8) for cases between 1996 and 2000, 7.8% (95% CI, 7.3–
8.3) for cases between 2001 and 2005 and 7.6% (95% CI, 6.9–8.4)
for cases between 2006 and 2010.
A difference of 25% in 5-year mortality estimates was seen for
patients diagnosed75 years old (52.0%, 95% CI, 47.0–57.1)
compared with those diagnosed40 years old (26.9%, 95% CI,
13.1–50.5) (Figure 2B). BCSM by age is presented in Figure 3.
Outcomes in relation to biological markers (ER, PR,
AR, HER2, Ki67) for M0 patients
Due to the very low number of ER-negative tumors, the associa-
tion of ER with outcome could not be assessed. We therefore
looked at the prognostic value of the level of positivity. Median
RFS of 6.4 years (95% CI, 3.6–11.8) and median OS of 7.8 years
(95% CI, 4.4–15.0) were observed for patients with low ER expres-
sion (Allred scores 3–6), whereas for those with high ER expression
(Allred scores 7–8), median RFS and OS were 7.5 years (95%
CI, 6.8–8.4) and 9.4 years (95% CI, 8.6–10.4), respectively
(Figure 4A).
Patients with negative PR expression (Allred scores 0–2) had
median RFS and OS of 6.9 years (95% CI, 5.2–9.5) and 8.4 years
(95% CI, 6.6–10.5), respectively; patients with low PR expression
(Allred scores 3–6) had median RFS and OS of 6.5 years (95% CI,
5.6–7.8) and 8.4 years (95% CI, 7.3–9.7), respectively; and
patients with high PR expression (Allred scores 7–8) had median
RFS and OS of 8.6 years (95% CI, 7.3–11.2) and 11.2 years (95%
CI, 9.3–14.7), respectively (Figure 4C).
There were also very few patients with negative AR expression
(Allred scores 0–2), which makes the comparison between negative
and positive AR difficult and very wide confidence intervals, not
allowing for a final conclusion; we therefore also looked at the prog-
nostic value of the level of positivity. Patients with low AR
expression(Allred scores 3–6) had median RFS and OS of 5.9 years
(95% CI, 4.7–7.8) and 7.0 years (95% CI, 5.8–9.4), respectively;
and those with high AR expression (Allred scores 7–8) had median
RFS and OS of 7.4 years (95% CI, 6.7–8.3) and 9.3 years (95% CI,
8.4–10.5), respectively (Figure 4B).
Supplementary Figure S4, available at Annals of Oncology online,
depicts OS according to Ki67 expression (no significant differences)
and supplementary Figure S5, available at Annals of Oncology online,
according to HER-2 status (no significant differences).






Reason not eligible N (%)
Female and/or No inv. BC 12 (54.5)
Year of diagnosis < 1990 8 (36.4)
Year of diagnosis > 2010 2 (9.1)
Central assessment(s)
of ER, PR, AR, HER2
and/or Ki67 available
(N¼1483)
82.4% of eligible patients
Analysis population
Central assessment(s)
of ER, PR, AR, HER2
and/or Ki67 not
available (N¼317)






























Insufficient material 80 (35.2)
Additional biomarker
assessment
grade, histology,. . .
central laboratory EU 2
Missing cores 38 (16.7)
Too thin 37 (16.3)







No block identifier 12 (5.3)
Nodal sample 6 (2.6)
Other/missing 10 (4.3)
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Outcomes in relation to histological grade for M0
patients
Median OS for patients with grade 1 tumors was 12.8 years (95%
CI, 10.3–15.4), for those with grade 2 tumors was 10.3 years (95%
CI, 8.4–11.3) and for those with grade 3 tumors was 9.0 years
(95% CI, 6.5–12.9) (Figure 4E). The HR for death for grade 3 ver-
sus grade 1–2 was 1.17 (P¼ 0.218).
Outcomes in relation to IHC surrogate of molecular
subtype for M0 patients
For Luminal A-like BC, median RFS was 8.3 years (95% CI, 7.1–
9.6) and median OS was 9.5 years (95% CI, 8.4–11.2). For
Luminal B-like/HER-2-negative BC, median RFS was 6.7 years
(95% CI, 5.8–7.9) and median OS was 8.8 years (95% CI, 7.9–
10.5). For Luminal B-like/HER-2-positive BC, median RFS was
10.0 years (95% CI, 5.9–11.2) and median OS was 10.0 years
(95% CI, 7.23 to Not estimable) (Figure 4D). Information
regarding triple-negative subtype is not reported due to limited
number of patients.
Discussion
Our study is the largest published series of male BC patients with
centrally reviewed clinical data and tumor samples. These results
Table 3. Patient and tumor characteristics by period of diagnosis
Period of diagnosis Total
(N 5 1483)










N (%) N (%) N (%) N (%) N (%) (% excl. Missing)
Age at diagnosis No significant trend
(P¼ 0.589)40 5 (2.2) 4 (1.3) 8 (1.8) 7 (1.4) 24 (1.6)
41–50 18 (8.0) 31 (9.8) 28 (6.1) 40 (8.3) 117 (7.9)
51–65 63 (28.0) 97 (30.6) 144 (31.5) 148 (30.6) 452 (30.5)
66–75 77 (34.2) 93 (29.3) 134 (29.3) 147 (30.4) 451 (30.4)
>75 62 (27.6) 92 (29.0) 143 (31.3) 142 (29.3) 439 (29.6)
Median 69.0 67.9 69.1 67.9 68.4
M status at diagnosis No significant trend
(P¼ 0.105)M0 135 (60.0) 185 (58.4) 344 (75.3) 390 (80.6) 1054 (71.1) (94.9)
M1 7 (3.1) 16 (5.0) 19 (4.2) 15 (3.1) 57 (3.8) (5.1)
Mx 83 (36.9) 116 (36.6) 94 (20.6) 79 (16.3) 372 (25.1)
For M0 patients (at diagnosis): (N¼135) (N¼185) (N¼ 344) (N¼390) (N¼1054) No significant trend
(P¼ 0.962)pN status
pN0 75 (55.6) 99 (53.5) 184 (53.5) 234 (60.0) 592 (56.2)
pN1 40 (29.6) 49 (26.5) 112 (32.6) 120 (30.8) 321 (30.5)
pN2 7 (5.2) 9 (4.9) 20 (5.8) 17 (4.4) 53 (5.0)
pN3 2 (1.5) 7 (3.8) 8 (2.3) 13 (3.3) 30 (2.8)
Nx 11 (8.1) 21 (11.4) 20 (5.8) 6 (1.5) 58 (5.5)
For M1 patients (at diagnosis): (N¼7) (N¼16) (N¼19) (N¼15) (N¼57)
Site of M
Bone 1 (14.3) 1 (6.3) 4 (21.1) 4 (26.7) 10 (17.5)
Lung 0 (0.0) 0 (0.0) 3 (15.8) 3 (20.0) 6 (10.5)
Soft tissue 0 (0.0) 0 (0.0) 1 (5.3) 0 (0.0) 1 (1.8)
Distant lymph node 0 (0.0) 2 (12.5) 1 (5.3) 0 (0.0) 3 (5.3)
Skin/subcutaneous 0 (0.0) 1 (6.3) 0 (0.0) 1 (6.7) 2 (3.5)
Other 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.7) 1 (1.8)
Combination 3 (42.9) 6 (37.5) 7 (36.8) 6 (40.0) 22 (38.6)
Missing 3 (42.9) 6 (37.5) 3 (15.8) 0 (0.0) 12 (21.1)
Overall, there is a percentage of missing data for most variables, similar to that observed in clinical trials. However, for the Netherlands, there is a larger
group of patients for whom a higher percentage of missing baseline, disease status and treatment data exist. Because this is a retrospective study, this issue
could not be prevented or resolved, and because for many of these patients central pathology assessment is available, they were included in the analysis
population. To investigate a possible selection bias when reporting such percentages, the nonmissing variables have been compared across countries for
a few important covariates. We concluded that there is no evidence for a selection bias when interpreting the percentages restricted to the nonmissing
data or when excluding patients with missing locoregional or distant progression status from the RFS analysis. However, because a potential bias cannot
be totally excluded, OS results should be considered more reliable than RFS results. pN status according to AJCC 7. The test for a trend over time for age,
M status and N status corresponds to the score test in a logistic regression (cumulative logit for age and N stage) with the date of diagnosis expressed in
decades as a covariate. OS, overall survival; RFS, relapse-free survival.
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show that the majority of male BC cases are ductal invasive carci-
nomas, with very low incidence of invasive lobular carcinoma.
This can be partially explained by the infrequent formation of ter-
minal lobules in male breast tissues, a phenomenon associated
with estrogen exposure in females, although there are some case
reports of invasive lobular carcinomas in male patients [21–23].
The majority of these tumors are grade 2, as previously
reported [2, 24–26] but importantly we found no association
between histological grade and outcome (univariate models) as
previously seen in a small Swedish study [27] but not seen in the
second largest international series [24]. If confirmed, this finding
has clinical implications for treatment decision making regarding
adjuvant chemotherapy, in particular for N0 disease.
Regarding the expression of the common receptors, we found that
male BC is almost always ERþ, PRþ and ARþ. A trend towards
higher OS was observed in patients with highly ERþ disease, highly
Table 4. Patterns of treatment by period of diagnosis
Early breast cancer (M0) treatment (local and/or systematic)









Total Test for trend
over time
N (%) N (%) N (%) N (%) N (%) (% excl. Missing)
Breast surgery No significant trend
(P¼0.979)No surgery 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.1) (0.1)
Breast-conserving surgery 3 (2.2) 10 (5.4) 9 (2.6) 11 (2.8) 33 (3.1) (4.0)
(Modified) radical mastectomy 95 (70.4) 148 (80.0) 261 (75.9) 290 (74.4) 794 (75.3) (95.9)
Missing 37 (27.4) 27 (14.6) 73 (21.2) 89 (22.8) 226 (21.4)
Management of regional nodes Significant trend
(P<0.001)Nothing 9 (6.7) 14 (7.6) 14 (4.1) 10 (2.6) 47 (4.5) (5.7)
ALND þ/ SNB 89 (65.9) 137 (74.1) 211 (61.3) 191 (49.0) 628 (59.6) (76.4)
SNB 1 (0.7) 4 (2.2) 46 (13.4) 96 (24.6) 147 (13.9) (17.9)
Missing 36 (26.7) 30 (16.2) 73 (21.2) 93 (23.8) 232 (22.0)
Adjuvant radiotherapy No significant trend
(P¼0.3874)No 49 (36.3) 73 (39.5) 147 (42.7) 153 (39.2) 422 (40.0) (51.5)
Yes 48 (35.6) 81 (43.8) 123 (35.8) 145 (37.2) 397 (37.7) (48.5)
Missing 38 (28.1) 31 (16.8) 74 (21.5) 92 (23.6) 235 (22.3)
(Neo)adjuvant chemotherapy Significant trend
(P<0.001)No 82 (60.7) 128 (69.2) 179 (52.0) 187 (47.9) 576 (54.6) (70.2)
Yes 14 (10.4) 28 (15.1) 91 (26.5) 112 (28.7) 245 (23.2) (29.8)
Missing 39 (28.9) 29 (15.7) 74 (21.5) 91 (23.3) 233 (22.1)




CMF 9 (6.7) 6 (3.2) 18 (5.2) 3 (0.8) 36 (3.4) (4.4)
Anthracycline based 4 (3.0) 18 (9.7) 49 (14.2) 34 (8.7) 105 (10.0) (12.8)
Anthracyclines and taxanes 0 (0.0) 1 (0.5) 18 (5.2) 60 (15.4) 79 (7.5) (9.6)
Other 0 (0.0) 2 (1.1) 4 (1.2) 13 (3.3) 19 (1.8) (2.3)
Missing 1 (7.1) 1 (3.6) 2 (2.2) 2 (1.8) 6 (2.5) (0.7)
Adjuvant endocrine therapy Significant trend
(P<0.001)No 53 (39.3) 69 (37.3) 41 (11.9) 26 (6.7) 189 (17.9) (23.2)
Yes 44 (32.6) 84 (45.4) 227 (66.0) 272 (69.7) 627 (59.5) (76.8)
Missing 38 (28.1) 32 (17.3) 76 (22.1) 92 (23.6) 238 (22.6)
If yes, specify planned treatment Significant trend
(P¼0.0011)
Tamoxifen 41 (30.4) 77 (41.6) 196 (57.0) 240 (61.5) 554 (52.6) (67.9)
Aromatase inhibitor (AI) 0 (0.0) 1 (0.5) 11 (3.2) 20 (5.1) 32 (3.0) (3.9)
Tamoxifen followed by AI 0 (0.0) 4 (2.2) 14 (4.1) 8 (2.1) 26 (2.5) (3.2)
Tamoxifen þ LHRH 0 (0.0) 0 (0.0) 6 (1.7) 1 (0.3) 7 (0.7) (0.9)
AIþ LHRH 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) (0.0)
Other 3 (2.2) 2 (1.1) 0 (0.0) 3 (0.8) 8 (0.8) (1.0)
The test for a trend over time corresponds to the score test in a logistic model (generalized logit for breast surgery, nodal management, chemotherapy
regimen and endocrine therapies) with the date of diagnosis expressed in decades as a covariate.
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Table 5. Results from central pathology review for early breast cancer (M0) patients
M0 (N 5 1054) Total Test trend over time
N (%) (% excluding Missing)
ER central laboratory (Allred score pooled) No significant trend
(P¼ 0.8762)0–2 7 (0.7) (0.7)
3–4 20 (1.9) (1.9)
5–6 41 (3.9) (4.0)
7–8 967 (91.7) (93.4)
Missing 19 (1.8)
PR central laboratory (Allred score) Significant trend (P¼ 0.028)
Average increase in
Allred score of 0.45 per
10-year period
0–2 184 (17.5) (18.1)
3–4 221 (21.0) (21.7)
5–6 228 (21.6) (22.4)
7–8 385 (36.5) (37.8)
Missing 36 (3.4)
AR central laboratory (Allred score) No significant trend
(P¼ 0.2135)0–2 32 (3.0) (3.1)
3–4 28 (2.7) (2.7)
5–6 67 (6.4) (6.5)
7–8 900 (85.4) (87.6)
Missing 27 (2.6)
KI67 central laboratory (cut at 14% and 20%) Significant trend (P< 0.001)
0%–<14% 633 (60.1) (61.3) Average increase in % of
positive cells of 4.9 per
10-year period
14%–<20% 145 (13.8) (14.0)
20%–100% 255 (24.2) (24.7)
Missing 21 (2.0)
KI67 central laboratory (cut at 20%)
0%–<20% 778 (73.8) (75.3)
20%–100% 255 (24.2) (24.7)
Missing 21 (2.0)
HER2 central laboratory No significant trend
(P¼ 0.407)Negative 935 (88.7) (89.6)
Positive 91 (8.6) (8.7)
Equivocal 18 (1.7) (1.7)
Missing 10 (0.9)
Clinico-pathological subtypes (2013 St Gallen consensus)
Luminal A 417 (39.6) (41.9)
Luminal B HER2 483 (45.8) (48.6)
Luminal B HER2þ 89 (8.4) (8.9)
HER2 positive (nonluminal) 2 (0.2) (0.2)
Basal 3 (0.3) (0.3)
Not defined (ER, PRþ) 0 (0.0) (0.0)
Missing 60 (5.7)
Histological type
Invasive ductal 678 (64.3) (84.8)
Mixed type 51 (4.8) (6.4)
Mucinous 10 (0.9) (1.3)
Invasive lobular classic 5 (0.5) (0.6)
Cribriform pure 5 (0.5) (0.6)
Invasive lobular variant 3 (0.3) (0.4)
Tubular pure 3 (0.3) (0.4)
Adenoid-cystic 3 (0.3) (0.4)
Invasive papillary 2 (0.2) (0.3)
No cancer on slide 1 (0.1) (0.1)
Other 39 (3.7) (4.9)
Missing 254 (24.1)
Histological grade
I 171 (16.2) (21.5)
Continued
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PRþ disease and highly ARþ (Allred scores 7–8) as compared with
low expression of the receptor (Allred scores 3–6). However, due to
low numbers of cases with absence of these receptors and lack of
treatment standardization in this retrospective series, the prognostic
value of all biomarkers requires confirmation, which is planned in
the ongoing prospective part of the International Male BC Program.
HER-2 expression was uncommon, and no association between out-
come and HER-2 status was seen.
Table 5. Continued
M0 (N 5 1054) Total Test trend over time
N (%) (% excluding Missing)
II 409 (38.8) (51.5)
III 214 (20.3) (27.0)
Missing 260 (24.7)
The test for a trend over time for ER, PR, AR and Ki-67 corresponds to the F-test in a linear model for the Allred scores and the percentage of positive cells
for Ki-67 as a response and with the date of diagnosis expressed in decades as a covariate. The test for a trend over time for HER2 corresponds to the score
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Figure 1. (A) Overall survival Kaplan–Meier curves for all patients, by stage of diagnosis. Events considered for this endpoint were death by
any cause. (B) Relapse-free survival Kaplan–Meier curves for early breast cancer (M0) patients by nodal status. Events considered for this end-
point were locoregional recurrence, distant progression and death by any cause.
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Figure 2. Overall mortality Kaplan–Meier curves for all patients by time period of diagnosis and by age at diagnosis. Events considered for
this endpoint were death by ay cause, the same as for overall survival (the reverse of the mortality numbers).
Annals of Oncology Original article
Volume 29 | Issue 2 | 2018 doi:10.1093/annonc/mdx651 | 413
High (20%) Ki67 expression was seen in only 24.9% of cases.
Utilizing IHC surrogates, the majority of patients had a Luminal
B-like/HER-2-negative (48.6%) or a Luminal A-like (41.9%) dis-
ease. Despite the current debate about the high degree of inter-
laboratory variation in Ki-67, the cut-off of 20% was considered
to define IHC surrogates for BC subtypes based on an adaptation
of the 2013 St Gallen consensus guidelines. There was no associa-
tion between OS and Ki67 or IHC surrogates for BC subtypes.
Previous reported data on molecular subtyping and genomic
profiling of male BC tumors are scarce. Most cases have been clas-
sified as Luminal-A-like or Luminal-B-HER-2-negative-like [28],
with significant differences between male and female BC samples
[24, 26, 29, 30]. However, in some of these studies distinction
between Luminal A and B was not clear, namely without any pro-
liferation measure associated [24]. Our work of deep character-
ization of male BC samples is ongoing, namely using RNA
sequencing and the Nanostring platform, and these results are
expected to detect important biological differences between BC
in males and females, with potential clinical implications.
The low number of HER-2þ and triple-negative BC in our series,
also observed in previous reports [24, 26, 31–33], lead us to recom-
mend a second pathology review whenever these subtypes are
reported in male BC patients, before treatment decisions are made.
Regarding the disease management throughout the 20-year period
of the current study, some troublesome findings deserve discussion.
Although 48.5% of patients had T1 tumors, only 4% percentage had
BCS. This is consistent with smaller retrospective reports and can be
explained partially by the male breast anatomy and mainly by old
practice patterns. Evaluation of less aggressive approaches, such as
BCS with or without oncoplastic techniques, as well as nipple-
sparing and skin-sparing mastectomies, is clearly needed. However,
the fact that the majority if not all BCs occurring in males develop
centrally, beneath the nipple, may impact surgical decisions.
SLNB has been proved feasible in men, and we observed a sig-
nificant trend over the years towards a less aggressive axillary
nodal management, showing that this procedure is gradually
being implemented in this patient population (P< 0.001).
In our series, adjuvant RT was not delivered to 45% patients
treated with BCS (regardless of nodal status), nor to a significant
proportion (30.7%) of patients with node positive tumors treated
with mastectomy. Since current recommendations suggest the
use of similar algorithms for RT decision-making in male as in
female BC patients, and male patients usually have a higher stage
at diagnosis, these low rates of adjuvant RT are a major concern.
We observe a significant trend over time toward increased che-
motherapy (anthracycline) use (P< 0.001). Since male BC is
mainly of Luminal subtype, future studies should evaluate the
role of proliferation biomarkers and genomic tools, to assist in
patient selection for adjuvant chemotherapy.
Even though ER was highly positive in>90% of cases, adjuvant
ET was given only to 76.8% patients. The reasons for this under-
use of an effective and low toxicity therapy are unknown.
Fortunately, we observed significantly more administration of
adjuvant tamoxifen in recent years (P< 0.001). Furthermore,
some patients received adjuvant aromatase inhibitors, a treat-
ment that cannot be recommended in male patients, without an
LHRH agonist. In males, 80% of circulating estrogens result from
peripheral aromatization of androgens and 20% are directly
secreted by the testicles [34, 35]. Aromatase inhibitors reduce
estradiol by 50% and increase testosterone levels by 5% [36], and
hypothalamic–pituitary negative feedback loop interferes with
marked estrogen suppression by aromatase inhibitors in men, in
the absence of (chemical) castration. Consequently, aromatase
inhibitors should be avoided unless used in association with med-
ical or surgical orchiectomy, which obviously has much higher
toxicity than tamoxifen alone. In a small MD Anderson cohort,
tamoxifen was associated with decreased recurrence and
improved OS (HR¼ 0.45, P¼ 0.01) [11]. In a retrospective anal-
ysis of SEER data and another from the German Cancer Registry,
survival among early male BC patients was improved with the use
100
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Figure 3. (A) Breast cancer–specific mortality Kaplan–Meier curves for all patients by age at diagnosis. Due to missing data, for breast cancer
mortality, only deaths following a distant relapse were considered events. All other deaths, not preceded by a distant relapse, were censored
on the death date. (B) Kaplan–Meier curves for age-adjusted breast cancer mortality by period of diagnosis. Patients were classified into four
age groups (41–50, 51–60, 61–70 and 71–80 years). Patients outside these groups are excluded. The breast cancer–specific mortality was cal-
culated separately for each age group, in each period of diagnosis. The plotted curve corresponds to a weighted analysis, where each of the
four age groups receives an equal weight within each period.
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of adjuvant tamoxifen but not with adjuvant aromatase inhibi-
tors [37, 38].
We acknowledge several limitations of the present study. Due
to its retrospective nature and the fact that not all data were sys-
tematically collected in all patients, the cohort studied may not
be entirely representative of the whole male BC population. For
certain variables, such as disease status at baseline and cause
of death, no information is available for a substantial number of
patients; therefore, the relative frequencies of the categories of
such variables and some of the outcome analysis (namely RFS)
may be biased due to selective missing data. We carried out sensi-
tivity analysis excluding patients with missing assessments (data
not shown) and could not find evidence for a selection bias.
Nevertheless, we consider that OS results may be more reliable
than RFS or BCSM results. The treatments received were not con-
trolled by a protocol and, given the rarity of the disease and
absence of randomized data, they were also not highly standar-
dized. Due to this heterogeneity, the findings regarding associa-
tions between biomarkers and outcomes should be taken with
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Figure 4. Overall survival Kaplan–Meier curves for early breast cancer (M0) patients (A) according to estrogen receptor (ER) expression (meas-
ured by Allred score); (B) according to androgen receptor (AR) expression (measured by Allred score); (C) according to progesterone receptor
(PR) expression (measured by Allred score); (D) according to immunohistochemistry (IHC) surrogate of molecular subtype and (E) according
to histological grade.
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Some of these limitations are being addressed in Part II of the
International Male BC Program, which consists of a prospective
registry of male BC patients, newly presenting at participating
sites, with prospective sample collection and quality of life
assessments.
Notwithstanding its limitations, the present study represents
an impressive worldwide effort to collect long-term clinical and
outcome data and centrally assessed biological information, for a
rare disease and is a model that could be followed for other rare
cancers. Our consortium will also soon provide prospective data
on the biology of male BC and clinical trial data evaluating news
therapies. The worrisome findings of lower quality of care pat-
terns seen call for the development of consensus guidelines and
the need for inclusion of male patients in BC clinical trials to
obtain the necessary information to guide treatment decisions in
this population.
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